IFRX Stock Overview
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.37 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$1.14 |
| Beta | 1.25 |
| 1 Month Change | -8.05% |
| 3 Month Change | -14.37% |
| 1 Year Change | -70.85% |
| 3 Year Change | -65.23% |
| 5 Year Change | -97.03% |
| Change since IPO | -90.86% |
Recent News & Updates
Recent updates
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08
InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Shareholder Returns
| IFRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.6% | -2.5% | -3.2% |
| 1Y | -70.9% | -3.7% | 19.3% |
Return vs Industry: IFRX underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: IFRX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| IFRX volatility | |
|---|---|
| IFRX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IFRX's share price has been volatile over the past 3 months.
Volatility Over Time: IFRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IFRX fundamental statistics | |
|---|---|
| Market cap | US$80.67m |
| Earnings (TTM) | -US$45.45m |
| Revenue (TTM) | US$67.20k |
1,200x
P/S Ratio-1.8x
P/E RatioIs IFRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IFRX income statement (TTM) | |
|---|---|
| Revenue | €63.09k |
| Cost of Revenue | €532.26k |
| Gross Profit | -€469.17k |
| Other Expenses | €42.20m |
| Earnings | -€42.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -743.67% |
| Net Profit Margin | -67,630.69% |
| Debt/Equity Ratio | 0% |
How did IFRX perform over the long term?
See historical performance and comparison